Phillips 2020.

Study name	A randomized, crossover comparison of ketamine and electroconvulsive therapy for treatment of major depressive episodes: a Canadian biomarker integration network in depression (CAN‐BIND) study protocol.
Methods	RCT
Participants	240 patients with major depressive disorder or bipolar disorder experiencing a MDE
Interventions	Randomised (1:1) to a course of ECT or racemic IV ketamine (0.5 mg/kg) administered 3 times/week for 3 or 4 weeks
Outcomes	The primary outcome measure is change in MADRS scores after randomised treatment as assessed by raters blind to treatment modality.
Starting date	Registered September 17, 2018.
Contact information	Jennifer.Phillips@theroyal.ca
Notes	Phillips 2020

ASA: American Society of Anaesthesiologists;BMI: body mass index;CGI: Clinical Global Impression scale;COPD: chronic obstructive pulmonary disease; DSM‐IV: Diagnostic and Statistical Manual of Mental Disorders, 4th Edition; ECT: electroconvulsive therapy; HDRS: Hamilton Depression Rating Scale; IM: intramuscular; IV: intravenous; MADRS: Montgomery‐Asberg Depression Rating Scale; MDD: Major Depressive Disorder; MRI: magnetic resonance imaging; MMSE: Mini Mental State Examination; PI: principal investigator; RCT: randomised controlled trial; SC: subcutaneous; SCID: Structured Clinical Interview for Depression; ULN: upper limit of normal.